Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in

therapeutic monoclonal antibodies Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAbs) to bind monospecifically to certain cells or proteins. The objective is that this treatment will stimulate the patient's immune system to attack those ...

. In May 2014, Alder went public. In early 2018, the company made a public stock offering, aiming to raise . The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas. As of September 2019, the Alder Biopharmaceuticals shares have increased with 83% in price, following the company's acquisition by the Denmark-based

H. Lundbeck H. Lundbeck A/S (commonly known simply as Lundbeck) is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are target ...

, in a deal valued at $1.95 billion. The company subsequently changed its name to Lundbeck Seattle Biopharmaceuticals after the acquisition.

References

American companies established in 2004 Biotechnology companies established in 2004 Pharmaceutical companies established in 2004 2004 establishments in Washington (state) Biotechnology companies of the United States Life sciences industry Pharmaceutical companies of the United States Health care companies based in Washington (state) Companies based in Bothell, Washington Biopharmaceutical companies Companies listed on the Nasdaq 2014 initial public offerings {{Med-company-stub